Douglas Earl Martin 4

What Happened

• Douglas Earl Martin, Allogene Therapeutics' Senior VP and General Counsel, had a sell-to-cover transaction and received new equity awards on Feb 2, 2026. He sold 22,900 shares in a mandated tax-withholding sale for a weighted average price of $1.76 per share (total ≈ $40,304). The filing also reports two derivative grants totaling 691,552 shares (no cash paid): one stock option grant and one restricted stock unit (RSU) award.

Key Details

• Transaction date: February 2, 2026; Form 4 filed Feb 4, 2026 (timely filing).
• Sale: 22,900 shares disposed, weighted avg price $1.76; sale prices ranged $1.71–$1.82 per F2.
• Grants: 539,072 and 152,480 derivative awards reported at $0.00 (no immediate cash outlay).
• Vesting notes: F3 describes the option vesting (25% after one year, then monthly over 36 months); F4 describes the RSU vesting (four equal annual installments beginning Feb 2, 2026).
• Tax withholding: F1 states the 22,900-share sale was a mandatory "sell-to-cover" to satisfy tax withholding and was not a discretionary sale.
• Shares owned after transaction: not disclosed in this filing.

Context

• The sale was a routine sell-to-cover tied to vesting/tax obligations, not an indicated market-timing trade. The larger items are the equity awards (options and RSUs), which vest over multiple years and represent compensation rather than an immediate market purchase.